The Role of Biotechnology in Europe's Responsible Innovation - 2010

 

Latest News Programme SME Award Location

Find the presentations and speeches of the event
Discover the pictures of the event.

 

Video of the event

 

Video address of European Commission President, José Manuel Barroso

 


Press release, 10 December 2010: EuropaBio Event: The European Biotechnology Industry Will Deliver on Responsible Innovation
Press release, 10 December 2010: Addex Pharmaceuticals wins EuropaBio’s Most Innovative European Biotech SME Award, 2010 
Press release, 2 December 2010: Europe’s brightest and best contend for EuropaBio’s Most Innovative SME Award, 2010


PRESS RELEASE

EuropaBio Event: The European Biotechnology Industry Will Deliver on Responsible Innovation

From Left to Right: Robert Johnstone, Patient;  Andrea Rappagliosi, EuropaBio Chairman;
John Dalli, European Commissioner for Health and Consumer Policy;
Sandra E. Peterson, Member of the Board of Management and Chief Executive Officer of Bayer CropScience AG;
Maria Gabriella Cruz, Fourth Generation Portuguese Farmer; Nathalie Moll, EuropaBio Secretary General.

 

Brussels, 10 December 2010

Yesterday, a broad range of regulators, CEOs, VCs, stakeholders, industry representatives and journalists met to share their perspectives on the role of biotechnology in contributing to the creation of Europe’s Innovation Union.

Speakers from across Europe in the healthcare, industrial and agricultural sectors communicated their views on how biotechnology is creating more jobs, improving lives and building a greener and healthier society. They outlined how these changes are being made through benefits in major areas of concern for European citizens including healthy living and ageing, climate change and food and energy security.

Speaking at the event, EuropaBio Chairman, Andrea Rappagliosi said: “Biotechnology has the potential to help make Europe a world-class science performer providing smart, sustainable and inclusive solutions for citizens, patients and consumers for 2020 and beyond. Our industry is willing to be held accountable for delivering products and solutions that have a demonstrable value in order to retain and strengthen state-of-the-art research and development in Europe. We are committed to playing our role in this process together with regulators, civil society and a broad range of stakeholders.”

In a video address, specially prepared for the event, President Barroso underlined that “Europe needs an innovative R&D oriented and responsible biotech industry. An industry which is rooted in the middle of our societies, because it offers concrete solutions to its many challenges, because it offers high quality employment, because it drives economic growth.”

Commissioner John Dalli, who gave the opening speech on the day, emphasised that “efforts by industry must be underpinned by a predictable regulatory environment and legal certainty for operators” in the context that “the European biotechnology industry has been a leader worldwide, from its research and development capacity to its success in diffusing these innovations globally.”

The event was concluded by the presentation of EuropaBio’s Most Innovative European Biotech SME Award by Paola Testori Coggi, Director General of DG Health and Consumer Policy to winners, Addex PharmaceuticalChris Maggos, Member of the Executive Management Boardof Addex Pharmaceuticals  received the Award on behalf the company together with a prize of €10,000 and two years free membership of EuropaBio.

EuropaBio Secretary General, Nathalie Moll concluded: “The support shown today to our existing and flourishing European biotechnology industry by President Barroso and by Commissioner Dalli are fundamental messages for EuropaBio and its members. In order for biotech to continue to provide the innovative solutions to some of society’s biggest challenges, we will need to work together to ensure a supportive regulatory and financial environment thatkeeps companies in Europe and attracts others to join us. Our commitment to communicating the benefits of this technology, to all audiences, is ongoing, and we look forward to playing our part in creating a smarter, more sustainable and more inclusive Europe. ”

ENDS.


Nathalie Moll
Secretary General, EuropaBio
Tel: +32 2 739 11 71;
Email: n.moll@europabio.org

Joanna Dupont Inglis
Communications Manager, EuropaBio
Tel: +32 2 739 11 84;
GSM: +32 476 60 71 35
Email: j.dupont@europabio.orG
 

EuropaBio is the European Association for Bioindustries, bringing together bioscience companies from all fields of research and development, testing, manufacturing and distribution of biotechnology products. It has 66 corporate and 7 associated members, 4 BioRegions and 22 National Biotechnology Associations representing some 1800 small and medium sized enterprises.

www.europabio.org
 


PRESS RELEASE

Addex Pharmaceuticals wins EuropaBio’s Most Innovative European Biotech SME Award, 2010 

(click on the link to watch the winning moment)
 
Chris Maggos from Addex Pharmaceuticals accepts the prize
together with Nathalie Moll, EuropaBio Secretary General,
Paola Testori Coggi, Director General DG Health and Consumer Policy and
Tom Saylor, Chair of EuropaBio’s SME Platform.

 


Brussels, 10 December 2010

Yesterday, at EuropaBio’s event on Innovation in Biotechnology, Addex Pharmaceuticals was revealed as the winner of EuropaBio’s Most Innovative European Biotech SME Award before an audience of EU regulators, CEOs, VCs, stakeholders, industry representatives and journalists.

Addex triumphed as winners over stiff competition from 31 other biotech companies demonstrating cutting edge innovation in biotechnology from across the healthcare, agricultural and industrial sectors.

The Geneva-based company, which was founded in 2002, was selected as the over all winner by a high-level judging panel from a final shortlist of five companies which also included AMSilk, KeyGene, Prosensa and TiGenix.

Addex Pharmaceuticals were honoured for their discoveries and developments in the field of allosteric modulators for human health focused on validated therapeutic targets for diseases of the central nervous system, metabolic disorders and inflammation.

Commenting on the significance of Addex’s work, EuropaBio Chairman, Andrea Rappagliosi said: “Addex showcases the critical role of European SMEs as a booster of knowledge and understanding of the diseases that are still a major unmet medical need in Europe. Addex has pioneered an extremely innovative solution to address important therapeutic areas such as Parkinson’s disease, schizophrenia, Alzheimer’s disease, endometriosis and benign prostatic hyperplasia. I would like to congratulate all five finalists. Choosing a winner was a tough task. ”

The company has demonstrated the potential of the technology by advancing products to Phase II clinical testing and partnering with two major pharmaceutical companies. In addition, Addex recently received a grant from the Michael J. Fox Foundation to support Phase II clinical testing of its lead product for Parkinson’s disease. Based upon its technology, which facilitates drug discovery for challenging therapeutic targets, Addex is developing products that may address some of the most important diseases such as Alzheimer’s, multiple sclerosis, type II diabetes, rheumatoid arthritis, depression and sleep disorders.

Tom Saylor, Chair of EuropaBio’s SME Platform added: “The applicants for this award have demonstrated how innovation is determined not only by technology, but also by developing sustainable business models which maximise the use of available funds and design products and services that bring life-enhancing changes for patients, consumers and the environment as a whole. At EuropaBio we will continue to help work towards removing bottlenecks for biotech SMEs – like expensive patenting, market fragmentation and slow standard setting– to help these vital innovators get their ideas to market responsibly and quickly.”

The winners were congratulated by President Barroso via a video message and the award was presented by Paola Testori Coggi, Director General of DG Health and Consumer Policy. Receiving the award on behalf of Addex together with a prize of €10,000 and two years free membership of EuropaBio, Chris Maggos, Member of the Executive Management of Addex Pharmaceuticals, said “Addex is honoured to receive the recognition of EuropaBio and to beselected from amongst such an outstanding group of SMEs in this field.” Reacting to the news,Addex’s CEO Vincent Mutel added: “We look forward to bringing allosteric modulators topatients as medical therapies, starting with our lead products for Parkinson’s disease andschizophrenia which will enter phase II clinical trial testing in the next few weeks. Our earlystage products include drugs for Alzheimer’s disease, diabetes and arthritis, all potentiallyimportant therapies for our aging population.”

Commenting on the competition as a whole, Dr Paul Rübig, MEP and President of SME Globalwho made up part of the judging panel for the award said “The overall quality and level ofinnovation demonstrated by the applicants was outstanding. There were many entriesdeveloping beneficial products for patients, consumers and the environment and selecting onlyone as a winner was a hard task. I wholeheartedly congratulate Addex on their achievement innot only pioneering innovation in their field but for doing so in a challenging regulatory andeconomic climate for SMEs”.

ENDS.

 

For further information on the award or on The Role of Biotechnology in Europe’s Responsible Innovation Event please contact:

 

Nathalie Moll
Secretary General, EuropaBio 
Tel: +32 2 739 11 71;
Email: n.moll@europabio.org

Joanna Dupont Inglis
Communications Manager, EuropaBio
Tel: +32 2 739 11 84;
GSM: +32 476 60 71 35
Email: j.dupont@europabio.org
 

EuropaBio is the European Association for Bioindustries, bringing together bioscience companies from all fields of research and development, testing, manufacturing and distribution of biotechnology products. It has 66 corporate and 7 associated members, 4 BioRegions and 22 National Biotechnology Associations representing some 1800 small and medium sized enterprises.

www.europabio.org 


PRESS RELEASE

Europe’s brightest and best contend for EuropaBio’s Most Innovative SME Award, 2010

Brussels, 2 December 2010

 

EuropaBio’s first ever Most Innovative European Biotech SME Award has attracted an outstanding array of applications from 32 companies across 12 countries representing all sectors of the biotech industry. 

With such stiff competition, the panel of judges faced a tough task to identify the top five entries from which the overall winner will be announced at EuropaBio’s event on the Role of Biotechnology in Europe’s Responsible Innovation, in Brussels on 9 December.  The winning applicant will receive a prize of €10,000 as well as two year’s free membership of EuropaBio.

Commenting on the shortlisted applicants, Tom Saylor, Chair of EuropaBio’s SME Platform said: “The top five finalists are each, in their own way, aiming to help us to live longer, healthier and greener lives.  In creating this award we are seeking not only to raise awareness of the societal and environmental value of the work these enterprises are doing but also to reward the economic value brought by European Biotech SMEs who have developed sustainable business strategies, maximised the use of available funds for development and built and protected novel intellectual property”.

The finalists include Addex Pharmaceuticals, a company devoted to industrialising discovery and development of allosteric modulators as medicines to treat diseases of the central nervous system, inflammation and metabolic disorders; AMSilk, for creating a new class of biopolymers emulating the natural silk proteins produced by spiders on an industrial scale for many applications in fibres, coatings, and filmsfor pharmaceutical, cosmetic, composite and technical textile applications; Keygene,for developing molecular breeding solutions to produce more efficient food, feed, fuel, fiber, flower and fun crops with a lower environmental footprint; Prosensa, focusing on the discovery, development and commercialisation of RNA (ribonucleic acid) modulating therapeutics targeting genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative life threatening disorders such as Duchenne Muscular Dystrophy, Myotonic Dystrophy, Huntington's disease and Spinal Muscular Atrophy, and TiGenix which exploits the power of Regenerative Medicine, using  proprietary cell and biomaterials platforms, to develop durable therapies for the repair of damaged or diseased skeletal tissues such as cartilage, meniscus, ligaments and bone. The aim is a full restoration of the biological and mechanical functions of these tissues to prevent further degeneration of the joint and to halt the onset and progression of osteoarthritis.

Andrea Rappagliosi, EuropaBio Chairman and chair of the judging panel commented:“Europe is home to some hugely talented scientists and researchers, but it takes real drive, passion and personal commitment to also overcome the obstacles and barriers facing SMEs and to translate these gifts into solutions that benefit patients, consumers, society and our environment as a whole.”

Rappagliosi underlined: “EuropaBio is committed to improving the economic and regulatory environment for Biotech SMEs. We will continue to strengthen our partnership with the European Commission to ensure that the EU Strategy for 2020 and the recently announced Innovation Union will boost the setting of a competitive environment where these highly innovative companies can flourish and contribute to a healthier and greener society in Europe.”

Other members of the judging panel included Professor Reinhilde Veugelers, Advisor to the European Commission and Professor at the Faculty of Economics and Business at KU Leuven (BE) and Dr Paul Rübig, Member of the European Parliament and President of SME Global.

The Award will be presented to the winning SME by Ms Paola Testori Coggi, Director General of DG Health and Consumer Policy at EuropaBio’s event on Innovation in Biotech on 9 December.  The event will be opened by an address from Commissioner John Dalli, will include a video address from President Barroso and will feature a set of select, high level presentations on innovation from across the sectors by industry leaders and civil society speakers.

Nathalie Moll, Secretary General of EuropaBio concluded: “There is now only one week to go until the overall winner of our Most Innovative European Biotech SME Award is revealed. It’s an exciting time and from what we have already seen Europe is right to have high hopes and also great expectations of these small but brilliant enterprises.”

ENDS.
 

Link to summaries of top 5 shortlisted SMEs

Link to list and description of SME Applicants  

 

For further information on the award or on The Role of Biotechnology in Europe’s Responsible Innovation Event on 9 December please contact:

 

Nathalie Moll 
Secretary General, EuropaBio 
Tel: +32 2 739 11 71;
Email: n.moll@europabio.org

Joanna DupontInglis
Communications Manager, EuropaBio
Tel: +32 2 739 11 84;
GSM: +32 476 60 71 35
Email: j.dupont@europabio.org
 

EuropaBio is the European Association for Bioindustries, bringing together bioscience companies from all fields of research and development, testing, manufacturing and distribution of biotechnology products. It has 66 corporate and 7 associated members, 4 BioRegions and 22 National Biotechnology Associations representing some 1800 small and medium sized enterprises.

www.europabio.org